메뉴 건너뛰기




Volumn 10, Issue 4, 2012, Pages 411-422

An update on iron chelation therapy

Author keywords

Chelation therapy; Iron; Iron overload; Thalassaemia; Transfusion dependent disorders

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FBS 0701; FERRITIN; IRON CHELATING AGENT; UNCLASSIFIED DRUG;

EID: 84869991089     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0008-12     Document Type: Review
Times cited : (194)

References (101)
  • 1
    • 70349545970 scopus 로고    scopus 로고
    • Iron overload and toxicity: The hidden risk of multiple blood transfusions
    • Shander A, Cappellini MD, Goodnough L. Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox Sang 2009; 97: 185-97.
    • (2009) Vox Sang , vol.97 , pp. 185-197
    • Shander, A.1    Cappellini, M.D.2    Goodnough, L.3
  • 4
    • 29844436963 scopus 로고    scopus 로고
    • Objectives and methods of iron chelation therapy
    • Hershko C, Abrahamov A, Konijm AM, et al. Objectives and methods of iron chelation therapy. Bioinorg Chem Apl 2003; 1: 151-68.
    • (2003) Bioinorg Chem Apl , vol.1 , pp. 151-168
    • Hershko, C.1    Abrahamov, A.2    Konijm, A.M.3
  • 7
    • 78651287827 scopus 로고    scopus 로고
    • Iron overload in MDS-pathophysiology, diagnosis, and complications
    • Gattermann N, Rachmilewitz EA. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol 2011; 90: 1-10.
    • (2011) Ann Hematol , vol.90 , pp. 1-10
    • Gattermann, N.1    Rachmilewitz, E.A.2
  • 9
    • 0033760134 scopus 로고    scopus 로고
    • Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major
    • Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110: 971-7.
    • (2000) Br J Haematol , vol.110 , pp. 971-977
    • Telfer, P.T.1    Prestcott, E.2    Holden, S.3
  • 10
    • 10444255328 scopus 로고    scopus 로고
    • Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: A retrospective crosssectional study
    • Ardalan FA, Osquei MR, Toosi MN, Irvanloo G. Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: a retrospective crosssectional study. BMC Gastroenterol 2004; 4: 17.
    • (2004) BMC Gastroenterol , vol.4 , pp. 17
    • Ardalan, F.A.1    Osquei, M.R.2    Toosi, M.N.3    Irvanloo, G.4
  • 13
    • 0037125595 scopus 로고    scopus 로고
    • Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia
    • DOI 10.1016/S0140-6736(02)09740-4
    • Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360: 516-20. (Pubitemid 35232104)
    • (2002) Lancet , vol.360 , Issue.9332 , pp. 516-520
    • Anderson, L.J.1    Wonke, B.2    Prescott, E.3    Holden, S.4    Walker, J.M.5    Pennell, D.J.6
  • 14
    • 57049104663 scopus 로고    scopus 로고
    • Cardiac iron across different transfusiondependent diseases
    • Wood JC. Cardiac iron across different transfusiondependent diseases. Blood Rev 2008; 22 (Suppl 2):S14-S21.
    • (2008) Blood Rev , vol.22 , Issue.SUPPL. 2
    • Wood, J.C.1
  • 15
    • 33646387405 scopus 로고    scopus 로고
    • Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis
    • Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738-44.
    • (2006) Blood , vol.107 , pp. 3738-3744
    • Pennell, D.J.1    Berdoukas, V.2    Karagiorga, M.3
  • 16
    • 77950617863 scopus 로고    scopus 로고
    • Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia
    • Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010; 115: 2364-71.
    • (2010) Blood , vol.115 , pp. 2364-2371
    • Pennell, D.J.1    Porter, J.B.2    Cappellini, M.D.3
  • 17
    • 77953779950 scopus 로고    scopus 로고
    • The effect of deferasirox on cardiac iron in thalassemia major: Impact of total body iron stores
    • Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010; 116: 537-43.
    • (2010) Blood , vol.116 , pp. 537-543
    • Wood, J.C.1    Kang, B.P.2    Thompson, A.3
  • 18
    • 72449177984 scopus 로고    scopus 로고
    • Cardiac T2*magnetic resonance for prediction of cardiac complications in thalassemia major
    • Kirk P, Roughton M, Porter JB, et al. Cardiac T2*magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120: 1961-8.
    • (2009) Circulation , vol.120 , pp. 1961-1968
    • Kirk, P.1    Roughton, M.2    Porter, J.B.3
  • 20
    • 3042746877 scopus 로고    scopus 로고
    • Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major
    • DOI 10.1182/blood-2003-08-2841
    • Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104: 263-9. (Pubitemid 38879867)
    • (2004) Blood , vol.104 , Issue.1 , pp. 263-269
    • Davis, B.A.1    O'Sullivan, C.2    Jarritt, P.H.3    Porter, J.B.4
  • 21
    • 76549140036 scopus 로고
    • Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis
    • Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964; 30: 698-705.
    • (1964) Circulation , vol.30 , pp. 698-705
    • Engle, M.A.1    Erlandson, M.2    Smith, C.H.3
  • 23
    • 0031001278 scopus 로고    scopus 로고
    • Iron-chelating therapy and the treatment of thalassemia
    • Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-61. (Pubitemid 27121266)
    • (1997) Blood , vol.89 , Issue.3 , pp. 739-761
    • Olivieri, N.F.1    Brittenham, G.M.2
  • 24
    • 33646414765 scopus 로고    scopus 로고
    • A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia
    • Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455-62.
    • (2006) Blood , vol.107 , pp. 3455-3462
    • Cappellini, M.D.1    Cohen, A.2    Piga, A.3
  • 25
    • 0021225166 scopus 로고
    • Depletion of excessive liver iron stores with desferrioxamine
    • Cohen A, Martin M, Schwartz E. Depletion of excessive liver iron stores with desferrioxamine. Br J Haematol 1984; 58: 369-73. (Pubitemid 14002111)
    • (1984) British Journal of Haematology , vol.58 , Issue.2 , pp. 369-373
    • Cohen, A.1    Martin, M.2    Schwartz, E.3
  • 26
    • 12544260252 scopus 로고    scopus 로고
    • Prevalence of endocrine complications and short stature in patients with thalassaemia major: A multicenter study by the Thalassaemia International Federation (TIF)
    • Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia
    • De Sanctis V, Eleftheriou A, Malaventura C. Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev 2004; 2 (Suppl 2): 249-55.
    • (2004) Pediatr Endocrinol Rev , vol.2 , Issue.SUPPL. 2 , pp. 249-255
    • De Sanctis, V.1    Eleftheriou, A.2    Malaventura, C.3
  • 27
    • 0034651775 scopus 로고    scopus 로고
    • Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia
    • Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000; 95: 1229-36. (Pubitemid 30099831)
    • (2000) Blood , vol.95 , Issue.4 , pp. 1229-1236
    • Davis, B.A.1    Porter, J.B.2
  • 31
    • 34548708556 scopus 로고    scopus 로고
    • Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: A literature review
    • DOI 10.1111/j.1537-2995.2007.01416.x
    • Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007; 47: 1919-29. (Pubitemid 47438560)
    • (2007) Transfusion , vol.47 , Issue.10 , pp. 1919-1929
    • Delea, T.E.1    Edelsberg, J.2    Sofrygin, O.3    Thomas, S.K.4    Baladi, J.-F.5    Phatak, P.D.6    Coates, T.D.7
  • 32
    • 33646407268 scopus 로고    scopus 로고
    • Cardiac morbidity and mortality in deferoxamineor deferiprone-treated patients with thalassemia major
    • Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamineor deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733-7.
    • (2006) Blood , vol.107 , pp. 3733-3737
    • Borgna-Pignatti, C.1    Cappellini, M.D.2    De Stefano, P.3
  • 33
    • 80355129916 scopus 로고    scopus 로고
    • A pilot trial of deferiprone for neurodegeneration with brain iron accumulation
    • Abbruzzese G, Cossu G, Balocco M, et al. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 2011; 96: 1708-11.
    • (2011) Haematologica , vol.96 , pp. 1708-1711
    • Abbruzzese, G.1    Cossu, G.2    Balocco, M.3
  • 35
    • 38949197818 scopus 로고    scopus 로고
    • Redistribution of accumulated cell iron: A modality of chelation with therapeutic implications
    • DOI 10.1182/blood-2007-07-102335
    • Sohn YS, Breuer W, Munnich A, Cabantchik ZI. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 2008; 111: 1690-9. (Pubitemid 351213461)
    • (2008) Blood , vol.111 , Issue.3 , pp. 1690-1699
    • Sohn, Y.-S.1    Breuer, W.2    Munnich, A.3    Cabantchik, Z.I.4
  • 36
    • 84355166625 scopus 로고    scopus 로고
    • The challenges of adherence and persistence with iron chelation therapy
    • Porter JB, Evangeli M, El-Beshlway A. The challenges of adherence and persistence with iron chelation therapy. Int J Hematol 2011; 94: 453-60.
    • (2011) Int J Hematol , vol.94 , pp. 453-460
    • Porter, J.B.1    Evangeli, M.2    El-Beshlway, A.3
  • 37
    • 0034928342 scopus 로고    scopus 로고
    • Exploring the "iron shuttle" hypothesis in chelation therapy: Effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture
    • DOI 10.1067/mlc.2001.116487
    • Link G, Konijn AM, Breuer W, et al. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001; 138: 130-8. (Pubitemid 32696277)
    • (2001) Journal of Laboratory and Clinical Medicine , vol.138 , Issue.2 , pp. 130-138
    • Link, G.1    Konijn, A.M.2    Breuer, W.3    Cabantchik, Z.I.4    Hershko, C.5
  • 38
    • 77955379581 scopus 로고    scopus 로고
    • Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone
    • Evans P, Kayyali R, Hider RC, et al. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Transl Res 2010; 156: 55-67.
    • (2010) Transl Res , vol.156 , pp. 55-67
    • Evans, P.1    Kayyali, R.2    Hider, R.C.3
  • 39
    • 0042943205 scopus 로고    scopus 로고
    • Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone
    • DOI 10.1182/blood-2002-10-3280
    • Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102: 1583-7. (Pubitemid 37022545)
    • (2003) Blood , vol.102 , Issue.5 , pp. 1583-1587
    • Cohen, A.R.1    Galanello, R.2    Piga, A.3    De Sanctis, V.4    Tricta, F.5
  • 40
    • 34248635452 scopus 로고    scopus 로고
    • Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia
    • DOI 10.1182/blood-2007-02-065805
    • Henter JI, Karlén J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood 2007; 109: 5157-9. (Pubitemid 46890530)
    • (2007) Blood , vol.109 , Issue.12 , pp. 5157-5159
    • Henter, J.-I.1    Karlen, J.2
  • 43
    • 0038187626 scopus 로고    scopus 로고
    • Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: A retrospective analysis
    • Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88: 489-96. (Pubitemid 36648438)
    • (2003) Haematologica , vol.88 , Issue.5 , pp. 489-496
    • Piga, A.1    Gaglioti, C.2    Fogliacco, E.3    Tricta, F.4
  • 44
    • 80053488289 scopus 로고    scopus 로고
    • Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
    • Smith GC, Alpendurada F, Carpenter JP, et al. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. J Cardiovasc Magn Reson 2011; 13: 34.
    • (2011) J Cardiovasc Magn Reson , vol.13 , pp. 34
    • Smith, G.C.1    Alpendurada, F.2    Carpenter, J.P.3
  • 45
    • 70349567584 scopus 로고    scopus 로고
    • The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: A clinical observational study
    • Berdoukas V, Chouliaras G, Moraitis P, et al. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson 2009; 11: 20.
    • (2009) J Cardiovasc Magn Reson , vol.11 , pp. 20
    • Berdoukas, V.1    Chouliaras, G.2    Moraitis, P.3
  • 46
    • 0942298725 scopus 로고    scopus 로고
    • Comparative Efficacy of Desferrioxamine, Deferiprone and in Combination on Iron Chelation in Thalassemic Children
    • Gomber S, Saxena R, Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatr 2004; 41: 21-7. (Pubitemid 38139865)
    • (2004) Indian Pediatrics , vol.41 , Issue.1 , pp. 21-27
    • Gomber, S.1    Saxena, R.2    Madan, N.3
  • 47
    • 33748783066 scopus 로고    scopus 로고
    • A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia
    • Galanello R, Kattamis A, Piga A, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006; 91: 1241-3. (Pubitemid 44408435)
    • (2006) Haematologica , vol.91 , Issue.9 , pp. 1241-1243
    • Galanello, R.1    Kattamis, A.2    Piga, A.3    Fischer, R.4    Leoni, G.5    Ladis, V.6    Voi, V.7    Lund, U.8    Tricta, F.9
  • 48
    • 37049033278 scopus 로고    scopus 로고
    • A randomized controlled 1-year study of daily deferiprone plus twice weekly desferoxamine compared with daily deferiprone monotherapy in patients with thalassemia major
    • DOI 10.3324/haematol.11414
    • Aydinok Y, Ulger Z, Nart D, et al. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica 2007; 92: 1599-606. (Pubitemid 350248238)
    • (2007) Haematologica , vol.92 , Issue.12 , pp. 1599-1606
    • Aydinok, Y.1    Ulger, Z.2    Nart, D.3    Terzi, A.4    Cetiner, N.5    Ellis, G.6    Zimmermann, A.7    Manz, C.8
  • 49
    • 33646677440 scopus 로고    scopus 로고
    • Combined theraphy with desferrioxamine and deferiprone in beta thalassemia major patients transfusional iron overload
    • Daar S, Pathare AV. Combined theraphy with desferrioxamine and deferiprone in beta thalassemia major patients transfusional iron overload. An Hematol 2006; 85: 315-6.
    • (2006) An Hematol , vol.85 , pp. 315-316
    • Daar, S.1    Pathare, A.V.2
  • 50
    • 44449104925 scopus 로고    scopus 로고
    • Iron chelation in thalassemia: Combined or monotherapy? The Egyptian experience
    • El-Beshlaway A, Manz C, Naja M, et al. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol 2008; 87: 545-50.
    • (2008) Ann Hematol , vol.87 , pp. 545-550
    • El-Beshlaway, A.1    Manz, C.2    Naja, M.3
  • 51
    • 34247103036 scopus 로고    scopus 로고
    • A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance
    • DOI 10.1161/CIRCULATIONAHA.106.648790
    • Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115: 1876-84. (Pubitemid 46598901)
    • (2007) Circulation , vol.115 , Issue.14 , pp. 1876-1884
    • Tanner, M.A.1    Galanello, R.2    Dessi, C.3    Smith, G.C.4    Westwood, M.A.5    Agus, A.6    Roughton, M.7    Assomull, R.8    Nair, S.V.9    Walker, J.M.10    Pennell, D.J.11
  • 52
    • 44049102508 scopus 로고    scopus 로고
    • Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction
    • Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008; 10: 12.
    • (2008) J Cardiovasc Magn Reson , vol.10 , pp. 12
    • Tanner, M.A.1    Galanello, R.2    Dessi, C.3
  • 53
    • 79957483630 scopus 로고    scopus 로고
    • Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: Main findings and clinical follow-up of a large multicenter randomized clinical trial in beta-thalassemia major patients
    • Pantalone GR, Maggio A, Vitrano A, et al. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in beta-thalassemia major patients. Hemoglobin 2011; 35: 206-16.
    • (2011) Hemoglobin , vol.35 , pp. 206-216
    • Pantalone, G.R.1    Maggio, A.2    Vitrano, A.3
  • 56
    • 0037906104 scopus 로고    scopus 로고
    • Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia
    • Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43: 565-72. (Pubitemid 36613115)
    • (2003) Journal of Clinical Pharmacology , vol.43 , Issue.6 , pp. 565-572
    • Galanello, R.1    Piga, A.2    Alberti, D.3    Rouan, M.-C.4    Bigler, H.5    Sechaud, R.6
  • 57
    • 38049151217 scopus 로고    scopus 로고
    • Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study
    • Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008; 80: 168-76.
    • (2008) Eur J Haematol , vol.80 , pp. 168-176
    • Porter, J.1    Galanello, R.2    Saglio, G.3
  • 59
    • 70450127262 scopus 로고    scopus 로고
    • Efficacy and safety of deferasirox (exjade®) in pediatric patients with beta-thalassemia: Update of 4.7-year efficacy and safety form extension studies
    • abstract
    • Cappellini MD. Efficacy and safety of deferasirox (exjade®) in pediatric patients with beta-thalassemia: update of 4.7-year efficacy and safety form extension studies [abstract]. Blood 2008; 112: ABS3883.
    • (2008) Blood , vol.112
    • Cappellini, M.D.1
  • 60
    • 77950682176 scopus 로고    scopus 로고
    • Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion- dependent anemias
    • Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010; 95: 557-66.
    • (2010) Haematologica , vol.95 , pp. 557-566
    • Cappellini, M.D.1    Porter, J.2    El-Beshlawy, A.3
  • 61
    • 65349152022 scopus 로고    scopus 로고
    • Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: The ESCALATOR study
    • Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol 2009; 82: 458-65.
    • (2009) Eur J Haematol , vol.82 , pp. 458-465
    • Taher, A.1    El-Beshlawy, A.2    Elalfy, M.S.3
  • 62
    • 80052691105 scopus 로고    scopus 로고
    • Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years
    • Deugneir Y, Turlin B, Ropert M, et al. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years. Gastroenterology 2011; 141: 1202-11, 1211.e1-3.
    • (2011) Gastroenterology , vol.141
    • Deugneir, Y.1    Turlin, B.2    Ropert, M.3
  • 63
    • 78650996705 scopus 로고    scopus 로고
    • Continued improvement in myocardial T2*over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload
    • Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2*over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica. 2011; 96: 48-54.
    • (2011) Haematologica. , vol.96 , pp. 48-54
    • Pennell, D.J.1    Porter, J.B.2    Cappellini, M.D.3
  • 64
    • 77957314807 scopus 로고    scopus 로고
    • Safety of combined chelation therapy with deferasirox and deferoxaminein transfusion-dependent thalassemia
    • Abstract
    • Lal L. Safety of combined chelation therapy with deferasirox and deferoxaminein transfusion-dependent thalassemia [Abstract]. Blood 2009; 114: 2021.
    • (2009) Blood , vol.114 , pp. 2021
    • Lal, L.1
  • 65
    • 56149116825 scopus 로고    scopus 로고
    • Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload
    • Otto-Duessel M, Brewer C, Gonzalez I, Nick H, Wood JC. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematol 2008; 120: 123-8.
    • (2008) Acta Haematol , vol.120 , pp. 123-128
    • Otto-Duessel, M.1    Brewer, C.2    Gonzalez, I.3    Nick, H.4    Wood, J.C.5
  • 66
    • 58949098317 scopus 로고    scopus 로고
    • Reversal of iron-induced dilated cardiomyopathy during therapy with deferasirox in beta-thalassemia
    • Trad O, Hamdan MA, Jamil A, et al. Reversal of iron-induced dilated cardiomyopathy during therapy with deferasirox in beta-thalassemia. Pediatr Blood Cancer 2009; 52: 426-8.
    • (2009) Pediatr Blood Cancer , vol.52 , pp. 426-428
    • Trad, O.1    Hamdan, M.A.2    Jamil, A.3
  • 67
    • 79951776374 scopus 로고    scopus 로고
    • Iron chelation in thalassemia: Time to reconsider our comfort zones
    • Berdoukas V, Farmaki K, Wood JC, Coates T. Iron chelation in thalassemia: time to reconsider our comfort zones. Expert Rev Hematol. 2011; 4: 17-26.
    • (2011) Expert Rev Hematol , vol.4 , pp. 17-26
    • Berdoukas, V.1    Farmaki, K.2    Wood, J.C.3    Coates, T.4
  • 68
    • 0035138693 scopus 로고    scopus 로고
    • Deferoxamine pharmacokinetics
    • Porter JB. Deferoxamine pharmacokinetics. Semin Haematol 2001; 38 (1 Suppl 1): 63-8. (Pubitemid 32110273)
    • (2001) Seminars in Hematology , vol.38 , Issue.1 SUPPL. 1 , pp. 63-68
    • Porter, J.B.1
  • 69
    • 0028962119 scopus 로고
    • Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload
    • al-Refaie FN, Sheppard LN, Nortey P, et al. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol 1995; 89: 403-8.
    • (1995) Br J Haematol , vol.89 , pp. 403-408
    • Al-Refaie, F.N.1    Sheppard, L.N.2    Nortey, P.3
  • 71
    • 74049116227 scopus 로고    scopus 로고
    • Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major
    • Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010; 148: 466-75.
    • (2010) Br J Haematol , vol.148 , pp. 466-475
    • Farmaki, K.1    Tzoumari, I.2    Pappa, C.3    Chouliaras, G.4    Berdoukas, V.5
  • 72
    • 65349110837 scopus 로고    scopus 로고
    • Reduction in labile plasma iron during treatment with deferasirox, a oncedaily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia
    • Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a oncedaily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol 2009; 82: 454-7.
    • (2009) Eur J Haematol , vol.82 , pp. 454-457
    • Daar, S.1    Pathare, A.2    Nick, H.3
  • 73
    • 79961008228 scopus 로고    scopus 로고
    • Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years' follow-up
    • Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011; 118: 884-93.
    • (2011) Blood , vol.118 , pp. 884-893
    • Cappellini, M.D.1    Bejaoui, M.2    Agaoglu, L.3
  • 74
    • 43449119849 scopus 로고    scopus 로고
    • Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis
    • Park SJ, Han CW. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. J Korean Med Sci 2008; 23: 320-3.
    • (2008) J Korean Med Sci , vol.23 , pp. 320-323
    • Park, S.J.1    Han, C.W.2
  • 75
    • 77955268192 scopus 로고    scopus 로고
    • Deferasirox in iron-overloaded patients with transfusiondependent myelodysplastic syndromes: Results from the large 1-year EPIC study
    • Gattermann N, Arisch A, Schlag R, et al. Deferasirox in iron-overloaded patients with transfusiondependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010; 34: 1143-50.
    • (2010) Leuk Res , vol.34 , pp. 1143-1150
    • Gattermann, N.1    Arisch, A.2    Schlag, R.3
  • 76
    • 38349157810 scopus 로고    scopus 로고
    • Effect of transfusional iron intake on response to chelation therapy in betathalassemia major
    • Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in betathalassemia major. Blood 2008; 111: 583-7.
    • (2008) Blood , vol.111 , pp. 583-587
    • Cohen, A.R.1    Glimm, E.2    Porter, J.B.3
  • 77
    • 80053222965 scopus 로고    scopus 로고
    • Response of iron overload to deferasirox in rare transfusion-dependent anaemias: Equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias
    • Porter JB, Lin KH, Beris P, et al. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Eur J Haematol 2011; 87: 338-48.
    • (2011) Eur J Haematol , vol.87 , pp. 338-348
    • Porter, J.B.1    Lin, K.H.2    Beris, P.3
  • 78
    • 77952956043 scopus 로고    scopus 로고
    • Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy only
    • abstract
    • Fox F. Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy only [abstract]. Blood 2009; 114 (22): ABS1747.
    • (2009) Blood , vol.114 , Issue.22
    • Fox, F.1
  • 79
    • 70449715018 scopus 로고    scopus 로고
    • Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy
    • Leitch HA, Chase JM, Goodman TA, et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leukemia 2008; 2: 205-11.
    • (2008) Clin Leukemia , vol.2 , pp. 205-211
    • Leitch, H.A.1    Chase, J.M.2    Goodman, T.A.3
  • 80
    • 77952959079 scopus 로고    scopus 로고
    • Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies)
    • Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res 2010; 34: 864-70.
    • (2010) Leuk Res , vol.34 , pp. 864-870
    • Rose, C.1    Brechignac, S.2    Vassilief, D.3
  • 81
    • 66349122329 scopus 로고    scopus 로고
    • Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome
    • abstract
    • Sanz G. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]. Blood 2008; 112 (II): ABS640.
    • (2008) Blood , vol.112 , Issue.2
    • Sanz, G.1
  • 82
    • 77955268192 scopus 로고    scopus 로고
    • Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
    • Gattermann N, Finelli C, Porta MD, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010; 34: 1143-50.
    • (2010) Leuk Res , vol.34 , pp. 1143-1150
    • Gattermann, N.1    Finelli, C.2    Porta, M.D.3
  • 83
    • 77954338182 scopus 로고    scopus 로고
    • Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients
    • Oliva EN, Ronco F, Marino A, et al. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion 2010; 50: 1568-70.
    • (2010) Transfusion , vol.50 , pp. 1568-1570
    • Oliva, E.N.1    Ronco, F.2    Marino, A.3
  • 84
    • 77954253063 scopus 로고    scopus 로고
    • Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response
    • Breccia M, Loglisci G, Saiaroli A, et al. Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response. Acta Haematol 2010; 24: 46-8.
    • (2010) Acta Haematol , vol.24 , pp. 46-48
    • Breccia, M.1    Loglisci, G.2    Saiaroli, A.3
  • 85
    • 79960398677 scopus 로고    scopus 로고
    • Hematologic responses in myelodysplastic syndrome (MDS) patients treated with deferasirox: An EPIC post-hoc analysis using International Working Group (IWG) 2006 criteria
    • abstract
    • Gattermann N. Hematologic responses in myelodysplastic syndrome (MDS) patients treated with deferasirox: an EPIC post-hoc analysis using International Working Group (IWG) 2006 criteria [abstract]. Blood 2010; 116 (21): ABS2912.
    • (2010) Blood , vol.116 , Issue.21
    • Gattermann, N.1
  • 86
    • 84870009822 scopus 로고    scopus 로고
    • Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome
    • abstract
    • Molteni A. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]. Haematologica 2010; 95 (Suppl 2): ABS640.
    • (2010) Haematologica , vol.95 , Issue.SUPPL. 2
    • Molteni, A.1
  • 88
    • 33645717043 scopus 로고    scopus 로고
    • Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
    • DOI 10.1016/j.bbmt.2006.01.004, PII S1083879106000449
    • Kamble RT, Selby GB, Mims M, et al. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 506-10. (Pubitemid 43964819)
    • (2006) Biology of Blood and Marrow Transplantation , vol.12 , Issue.5 , pp. 506-510
    • Kamble, R.T.1    Selby, G.B.2    Mims, M.3    Kharfan-Dabaja, M.A.4    Ozer, H.5    George, J.N.6
  • 91
    • 33645724771 scopus 로고    scopus 로고
    • Iron-overload in long-term survivors of hematopoietic transplantation
    • Kamble R, Mims M. Iron-overload in long-term survivors of hematopoietic transplantation. Bone Marrow Transplant 2006; 37: 805-6.
    • (2006) Bone Marrow Transplant , vol.37 , pp. 805-806
    • Kamble, R.1    Mims, M.2
  • 92
    • 0242636489 scopus 로고    scopus 로고
    • Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia
    • DOI 10.1038/sj.bmt.1704244
    • Butt NM, Clark RE. Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia. Bone Marrow Transplant 2003; 32: 909-13. (Pubitemid 37369269)
    • (2003) Bone Marrow Transplantation , vol.32 , Issue.9 , pp. 909-913
    • Butt, N.M.1    Clark, R.E.2
  • 93
    • 33646049725 scopus 로고    scopus 로고
    • Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: A study of 367 myeloma patients
    • Miceli MH, Dong L, Grazziutti ML, et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 2006; 37: 857-64.
    • (2006) Bone Marrow Transplant , vol.37 , pp. 857-864
    • Miceli, M.H.1    Dong, L.2    Grazziutti, M.L.3
  • 95
    • 43049167385 scopus 로고    scopus 로고
    • Iron overload in myelodysplastic syndromes: A Canadian consensus guideline
    • Wells RA, Leber B, Buckstein R, et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leukemia Res 2008; 32: 1338-53.
    • (2008) Leukemia Res , vol.32 , pp. 1338-1353
    • Wells, R.A.1    Leber, B.2    Buckstein, R.3
  • 96
    • 36849075284 scopus 로고    scopus 로고
    • Iron chelation beyond transfusion iron overload
    • DOI 10.1002/ajh.21101
    • Pietrangelo A. Iron chelation beyond transfusion iron overload. Am J Hematol 2007; 82 (12 Suppl): 1142-6. (Pubitemid 350221246)
    • (2007) American Journal of Hematology , vol.82 , Issue.12 SUPPL. , pp. 1142-1146
    • Pietrangelo, A.1
  • 97
    • 37749054933 scopus 로고    scopus 로고
    • Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda
    • Gorman N, Zaharia A, Trask HS, et al. Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda. Hepatology 2007; 46: 1927-34.
    • (2007) Hepatology , vol.46 , pp. 1927-1934
    • Gorman, N.1    Zaharia, A.2    Trask, H.S.3
  • 99
    • 80051615717 scopus 로고    scopus 로고
    • Deferoxamine for advanced hepatocellular carcinoma
    • Yamasaki T, Terai S, Sakaida I. Deferoxamine for advanced hepatocellular carcinoma. N Engl J Med 2011; 365: 576-8.
    • (2011) N Engl J Med , vol.365 , pp. 576-578
    • Yamasaki, T.1    Terai, S.2    Sakaida, I.3
  • 100
    • 79953853812 scopus 로고    scopus 로고
    • A phase I dose-escalation study: Safety, tolerability, and pharmacokinetics of FBS070I, a novel iron chelator for the treatment of transfusional iron overload
    • Rienhoff HY Jr, Viprakasit V, Tay L, et al. A phase I dose-escalation study: safety, tolerability, and pharmacokinetics of FBS070I, a novel iron chelator for the treatment of transfusional iron overload. Haematologica 2010; 96: 521-5.
    • (2010) Haematologica , vol.96 , pp. 521-525
    • Rienhoff Jr., H.Y.1    Viprakasit, V.2    Tay, L.3
  • 101
    • 84859604828 scopus 로고    scopus 로고
    • A phase 2 study of the safety, tolerability and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload
    • Neufeld EJ, Galanello R, Viprakasit V, et al. A phase 2 study of the safety, tolerability and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood 2012; 119: 3263-8.
    • (2012) Blood , vol.119 , pp. 3263-3268
    • Neufeld, E.J.1    Galanello, R.2    Viprakasit, V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.